New research reveals RNA on leaves may impact microbial communities
Biologists at Indiana University Bloomington have shown that the surfaces of plant leaves are coated with a diverse array of ...
Pharmaceutical Technology9h
RBD-7022 by Suzhou Ribo Life Sciences for Hyperlipidemia: Likelihood of Approval
RBD-7022 is under clinical development by Suzhou Ribo Life Sciences and currently in Phase I for Hyperlipidemia.
GlobalData on MSN12d
Arrowhead doses first patient in Phase I/IIa RNA obesity therapy trial
The investigational therapy works to impede the expression of genes that cause the body to store fat as a potential treatment ...
The pendulum of scientific innovation
Through last year, scientists were at work reshaping human life and equipping it, and the world, for the challenges of the ...
Le Lézard13d
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
Arrowhead Pharmaceuticals, Inc. today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE, the company's investigational RNA interference (RNAi) therapeutic ...
5 coolest engineering innovations of 2024
From Zildjian to NASA ðŸ˜® By Andrew Rosenblum Posted on Dec 26, 2024 To keep global temperatures from rising more than 1.5 ...
gut.bmj3d
Construction of exosome non-coding RNA feature for non-invasive, early detection of gastric cancer patients by machine learning: a multi-cohort study
Background and objective Gastric cancer (GC) remains a prevalent and preventable disease, yet accurate early diagnostic ...
Silence Therapeutics to Transition to U.S. Issuer Status
Silence Therapeutics ( (SLN) ) has shared an announcement.
Arrowhead doses 1st patients in study of ARO-INHBE for obesity treatment
Pharmaceuticals announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE, the company’s ...